TECH
Bio-Techne Corporation
Price Chart
Latest Quote
$57.94
+2.94 (+5.35%)
Current Price
| Previous Close | $55.00 |
| Open | $55.54 |
| Day High | $58.25 |
| Day Low | $55.15 |
| Volume | 3,614,364 |
Stock Information
| Quarterly Dividend / Yield | $0.32 / 0.57% |
| Shares Outstanding | 156.57M |
| Quarterly Dividend Yield | 0.57% |
| Quarterly Dividend | $0.32 |
| Total Debt | $290.32M |
| Cash Equivalents | $214.11M |
| Revenue | $1.21B |
| Net Income | $109.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.07B |
| P/E Ratio | 82.77 |
| EPS (TTM) | $0.70 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.85B |
| Sales | $1.21B |
| Income | $109.50M |
| Book/sh | $12.90 |
| Cash/sh | $1.37 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 2.80 |
| Current Ratio | 4.49 |
| Debt/Eq | 13.92 |
| EPS Growth TTM | 126.00% |
Returns & Margins
| ROA | 7.45% |
| ROE | 5.34% |
| Gross Margin | 66.40% |
| Operating Margin | 25.19% |
| Profit Margin | 9.05% |
Ownership
| Insider Ownership | 0.31% |
| Institutional Ownership | 117.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.19 |
| PEG | 0.77 |
| P/S | 7.49 |
| P/B | 4.49 |
Analyst Data
| Recommendation | buy |
| Target Price | $61.69 |
Technical Indicators
| SMA20 | $52.17 |
| SMA50 | $52.44 |
| SMA200 | $57.32 |
| RSI | 66.77 |
| ATR | 2.0793 |
| Shares Float | 155.97M |
| Short Float | 10.09% |
| Short Ratio | 4.05 |
| Volatility | 1.36 |
| Rel Volume | 1.30 |
Performance History
| Week | +7.26% |
| Month | +27.42% |
| Quarter | +12.52% |
| 6 Months | +1.19% |
| YTD | -2.56% |
| Year | +17.76% |
| 3 Years | -23.31% |
| 5 Years | -46.61% |
| 10 Years | +122.03% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $57.94 | 3,628,977 |
| 2026-06-17 | $55.00 | 2,347,200 |
| 2026-06-16 | $56.03 | 1,529,600 |
| 2026-06-15 | $56.17 | 3,298,700 |
| 2026-06-12 | $54.00 | 2,558,200 |
| 2026-06-11 | $54.02 | 2,664,500 |
| 2026-06-10 | $52.50 | 2,648,800 |
| 2026-06-09 | $54.41 | 3,553,600 |
| 2026-06-08 | $52.65 | 4,440,000 |
| 2026-06-05 | $51.99 | 2,947,800 |
| 2026-06-04 | $53.18 | 4,200,600 |
| 2026-06-03 | $50.85 | 2,232,900 |
| 2026-06-02 | $49.77 | 2,282,200 |
| 2026-06-01 | $50.79 | 2,207,600 |
| 2026-05-29 | $51.68 | 2,928,100 |
| 2026-05-28 | $50.84 | 2,852,400 |
| 2026-05-27 | $48.09 | 2,151,100 |
| 2026-05-26 | $47.97 | 2,588,200 |
| 2026-05-22 | $48.21 | 2,535,200 |
| 2026-05-21 | $47.37 | 2,315,400 |
| 2026-05-20 | $46.70 | 2,806,300 |
| 2026-05-19 | $45.47 | 3,381,900 |
| 2026-05-18 | $nan | 0 |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
đ° Latest News
Bio-Techne (TECH) Stock Valuation After New Refeyn Bispecific Antibody Analysis Collaboration
Simply Wall St. âĸ 2026-06-16T00:16:03Z
Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers
Insider Monkey âĸ 2026-06-15T05:03:59Z
Is Bio-Techne Corporation (TECH) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-13T20:43:45Z
SpaceX initiated, Intel upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-11T13:38:31Z
1 S&P 500 Stock with Impressive Fundamentals and 2 We Brush Off
StockStory âĸ 2026-06-11T10:33:37Z
New Bispecific Antibody Characterization Workflow Might Change The Case For Investing In Bio-Techne (TECH)
Simply Wall St. âĸ 2026-06-08T21:19:50Z
3 Reasons TECH is Risky and 1 Stock to Buy Instead
StockStory âĸ 2026-06-08T17:17:50Z
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:30Z
3 of Wall Streetâs Favorite Stocks with Questionable Fundamentals
StockStory âĸ 2026-06-02T12:21:23Z
Are Wall Street Analysts Bullish on Bio-Techne Stock?
Barchart âĸ 2026-05-25T18:23:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $350,745,000 | $309,334,000 | $291,725,000 | $280,526,000 |
| Cost Of Revenue | $429,363,000 | $389,335,000 | $366,887,000 | $349,103,000 |
| Total Revenue | $1,219,635,000 | $1,159,060,000 | $1,136,702,000 | $1,105,599,000 |
| Operating Revenue | $1,219,635,000 | $1,159,060,000 | $1,136,702,000 | $1,105,599,000 |
| Expenses | ||||
| Interest Expense | $8,509,000 | $15,736,000 | $11,215,000 | $11,309,000 |
| Total Expenses | $976,831,000 | $912,659,000 | $845,704,000 | $809,771,000 |
| Other Income Expense | $-139,718,000 | $-48,299,000 | $55,466,000 | $16,073,000 |
| Other Non Operating Income Expenses | $36,000 | $330,000 | $469,000 | $1,461,000 |
| Net Non Operating Interest Income Expense | $-4,623,000 | $-12,413,000 | $-7,805,000 | $-10,515,000 |
| Interest Expense Non Operating | $8,509,000 | $15,736,000 | $11,215,000 | $11,309,000 |
| Operating Expense | $547,468,000 | $523,324,000 | $478,817,000 | $460,668,000 |
| General And Administrative Expense | $415,097,000 | $393,320,000 | $352,438,000 | $339,001,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $73,400,000 | $168,105,000 | $285,263,000 | $272,051,000 |
| Net Interest Income | $-4,623,000 | $-12,413,000 | $-7,805,000 | $-10,515,000 |
| Interest Income | $3,886,000 | $3,323,000 | $3,410,000 | $794,000 |
| Normalized Income | $178,215,540 | $205,923,140 | $237,936,980 | $259,294,724 |
| Net Income From Continuing And Discontinued Operation | $73,400,000 | $168,105,000 | $285,263,000 | $272,051,000 |
| Total Operating Income As Reported | $102,255,000 | $206,686,000 | $298,944,000 | $296,590,000 |
| Net Income Common Stockholders | $73,363,000 | $168,072,000 | $285,193,000 | $271,930,000 |
| Net Income | $73,400,000 | $168,105,000 | $285,263,000 | $272,051,000 |
| Net Income Including Noncontrolling Interests | $73,400,000 | $168,105,000 | $285,442,000 | $263,099,000 |
| Net Income Continuous Operations | $73,400,000 | $168,105,000 | $285,442,000 | $263,099,000 |
| Pretax Income | $98,463,000 | $185,689,000 | $338,659,000 | $301,386,000 |
| Special Income Charges | $-142,139,000 | $-41,345,000 | $6,136,000 | $-1,273,000 |
| Earnings From Equity Interest | $938,000 | $-6,841,000 | $-1,143,000 | $0 |
| Interest Income Non Operating | $3,886,000 | $3,323,000 | $3,410,000 | $794,000 |
| Operating Income | $242,804,000 | $246,401,000 | $290,998,000 | $295,828,000 |
| Depreciation Amortization Depletion Income Statement | $31,285,000 | $31,710,000 | $32,076,000 | $32,492,000 |
| Depreciation And Amortization In Income Statement | $31,285,000 | $31,710,000 | $32,076,000 | $32,492,000 |
| Amortization Of Intangibles Income Statement | $31,285,000 | $31,710,000 | $32,076,000 | $32,492,000 |
| Gross Profit | $790,272,000 | $769,725,000 | $769,815,000 | $756,496,000 |
| Per Share | ||||
| Diluted EPS | $0.46 | $1.05 | $1.76 | $1.66 |
| Basic EPS | $0.47 | $1.07 | $1.81 | $1.73 |
| Other | ||||
| Tax Effect Of Unusual Items | $-35,876,460 | $-3,969,860 | $8,813,980 | $1,855,724 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $357,567,000 | $354,924,000 | $400,972,000 | $399,152,000 |
| Total Unusual Items | $-140,692,000 | $-41,788,000 | $56,140,000 | $14,612,000 |
| Total Unusual Items Excluding Goodwill | $-140,692,000 | $-41,788,000 | $56,140,000 | $14,612,000 |
| Reconciled Depreciation | $109,903,000 | $111,711,000 | $107,238,000 | $101,069,000 |
| EBITDA (Bullshit earnings) | $216,875,000 | $313,136,000 | $457,112,000 | $413,764,000 |
| EBIT | $106,972,000 | $201,425,000 | $349,874,000 | $312,695,000 |
| Diluted Average Shares | $159,717,000 | $160,774,000 | $161,855,000 | $164,116,000 |
| Basic Average Shares | $157,521,000 | $157,708,000 | $157,179,000 | $156,876,000 |
| Diluted NI Availto Com Stockholders | $73,363,000 | $168,072,000 | $285,193,000 | $271,930,000 |
| Otherunder Preferred Stock Dividend | $37,000 | $33,000 | $70,000 | $121,000 |
| Minority Interests | $0 | $0 | $-179,000 | $8,952,000 |
| Tax Provision | $25,063,000 | $17,584,000 | $53,217,000 | $38,287,000 |
| Other Special Charges | $41,827,000 | $3,506,000 | - | - |
| Write Off | $80,503,000 | $21,963,000 | $0 | $18,715,000 |
| Restructuring And Mergern Acquisition | $19,809,000 | $15,876,000 | $-6,136,000 | $-17,442,000 |
| Gain On Sale Of Security | $1,447,000 | $-443,000 | $50,004,000 | $15,885,000 |
| Other Taxes | $1,590,000 | $1,630,000 | $1,810,000 | $2,035,000 |
| Amortization | $31,285,000 | $31,710,000 | $32,076,000 | $32,492,000 |
| Research And Development | $99,496,000 | $96,664,000 | $92,493,000 | $87,140,000 |
| Selling General And Administration | $415,097,000 | $393,320,000 | $352,438,000 | $339,001,000 |
| Other Gand A | $374,237,000 | $353,868,000 | $312,169,000 | $293,916,000 |
| Salaries And Wages | $40,860,000 | $39,452,000 | $40,269,000 | $45,085,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $572,274,000 | $589,106,000 | $559,134,000 | $348,147,000 |
| Total Assets | $2,557,868,000 | $2,703,867,000 | $2,638,692,000 | $2,294,805,000 |
| Total Non Current Assets | $1,949,568,000 | $2,086,448,000 | $2,017,210,000 | $1,689,249,000 |
| Other Non Current Assets | $19,783,000 | $12,115,000 | $12,588,000 | $10,802,000 |
| Non Current Deferred Assets | $10,307,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $10,307,000 | $0 | - | - |
| Financial Assets | $2,843,000 | $9,813,000 | $16,857,000 | $11,026,000 |
| Goodwill And Other Intangible Assets | $1,346,534,000 | $1,479,744,000 | $1,407,382,000 | $1,353,623,000 |
| Other Intangible Assets | $365,599,000 | $507,081,000 | $534,645,000 | $531,522,000 |
| Current Assets | $608,300,000 | $617,419,000 | $621,482,000 | $605,556,000 |
| Other Current Assets | $37,460,000 | $33,658,000 | $27,066,000 | $22,856,000 |
| Assets Held For Sale Current | $12,332,000 | $9,773,000 | $0 | - |
| Inventory | $189,446,000 | $179,731,000 | $171,638,000 | $141,123,000 |
| Receivables | $206,876,000 | $241,394,000 | $218,468,000 | $194,548,000 |
| Accounts Receivable | $206,876,000 | $241,394,000 | $218,468,000 | $194,548,000 |
| Allowance For Doubtful Accounts Receivable | $-4,215,000 | $-4,386,000 | $-4,738,000 | $-2,568,000 |
| Gross Accounts Receivable | $211,091,000 | $245,780,000 | $223,206,000 | $197,116,000 |
| Cash Cash Equivalents And Short Term Investments | $162,186,000 | $152,863,000 | $204,310,000 | $247,029,000 |
| Cash And Cash Equivalents | $162,186,000 | $151,791,000 | $180,571,000 | $172,567,000 |
| Debt | ||||
| Net Debt | $183,814,000 | $167,209,000 | $169,429,000 | $83,343,000 |
| Total Debt | $444,058,000 | $419,538,000 | $454,965,000 | $325,971,000 |
| Long Term Debt And Capital Lease Obligation | $429,960,000 | $406,618,000 | $443,766,000 | $301,543,000 |
| Long Term Debt | $346,000,000 | $319,000,000 | $350,000,000 | $243,410,000 |
| Current Debt And Capital Lease Obligation | $14,098,000 | $12,920,000 | $11,199,000 | $24,428,000 |
| Current Debt | - | - | - | $12,500,000 |
| Other Current Borrowings | - | - | - | $12,500,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $639,060,000 | $635,017,000 | $672,176,000 | $593,794,000 |
| Total Non Current Liabilities Net Minority Interest | $463,211,000 | $475,638,000 | $543,667,000 | $417,776,000 |
| Other Non Current Liabilities | $27,082,000 | $13,157,000 | $10,919,000 | $12,239,000 |
| Non Current Deferred Liabilities | $6,169,000 | $55,863,000 | $88,982,000 | $98,994,000 |
| Non Current Deferred Taxes Liabilities | $6,169,000 | $55,863,000 | $88,982,000 | $98,994,000 |
| Current Liabilities | $175,849,000 | $159,379,000 | $128,509,000 | $176,018,000 |
| Other Current Liabilities | $1,645,000 | $2,151,000 | $1,413,000 | $1,243,000 |
| Current Deferred Liabilities | $32,571,000 | $27,930,000 | $23,069,000 | $23,406,000 |
| Payables And Accrued Expenses | $127,535,000 | $116,378,000 | $92,828,000 | $126,941,000 |
| Payables | $36,081,000 | $41,674,000 | $41,201,000 | $47,102,000 |
| Total Tax Payable | $10,770,000 | $3,706,000 | $12,022,000 | $13,237,000 |
| Income Tax Payable | $10,770,000 | $3,706,000 | $12,022,000 | $13,237,000 |
| Accounts Payable | $25,311,000 | $37,968,000 | $25,679,000 | $33,865,000 |
| Tradeand Other Payables Non Current | - | - | $0 | $5,000,000 |
| Other Payable | - | - | $3,500,000 | - |
| Equity | ||||
| Common Stock Equity | $1,918,808,000 | $2,068,850,000 | $1,966,516,000 | $1,701,770,000 |
| Total Equity Gross Minority Interest | $1,918,808,000 | $2,068,850,000 | $1,966,516,000 | $1,701,011,000 |
| Stockholders Equity | $1,918,808,000 | $2,068,850,000 | $1,966,516,000 | $1,701,770,000 |
| Gains Losses Not Affecting Retained Earnings | $-59,880,000 | $-78,316,000 | $-66,064,000 | $-75,200,000 |
| Other Equity Adjustments | $-59,880,000 | $-78,316,000 | $-66,064,000 | $-75,200,000 |
| Retained Earnings | $1,066,049,000 | $1,325,247,000 | $1,309,461,000 | $1,122,937,000 |
| Long Term Equity Investment | $235,983,000 | $242,337,000 | $255,857,000 | $25,000,000 |
| Investments In Other Ventures Under Equity Method | $235,983,000 | $242,337,000 | $255,857,000 | $25,000,000 |
| Other | ||||
| Ordinary Shares Number | $154,972,196 | $158,216,258 | $157,641,914 | $156,640,000 |
| Share Issued | $154,972,196 | $158,216,258 | $157,641,914 | $156,640,000 |
| Tangible Book Value | $572,274,000 | $589,106,000 | $559,134,000 | $348,147,000 |
| Invested Capital | $2,264,808,000 | $2,387,850,000 | $2,316,516,000 | $1,957,680,000 |
| Working Capital | $432,451,000 | $458,040,000 | $492,973,000 | $429,538,000 |
| Capital Lease Obligations | $98,058,000 | $100,538,000 | $104,965,000 | $70,061,000 |
| Total Capitalization | $2,264,808,000 | $2,387,850,000 | $2,316,516,000 | $1,945,180,000 |
| Minority Interest | $0 | $0 | $0 | $-759,000 |
| Additional Paid In Capital | $911,089,000 | $820,337,000 | $721,543,000 | $652,467,000 |
| Capital Stock | $1,550,000 | $1,582,000 | $1,576,000 | $1,566,000 |
| Common Stock | $1,550,000 | $1,582,000 | $1,576,000 | $1,566,000 |
| Long Term Capital Lease Obligation | $83,960,000 | $87,618,000 | $93,766,000 | $58,133,000 |
| Current Deferred Revenue | $32,571,000 | $27,930,000 | $23,069,000 | $23,406,000 |
| Current Capital Lease Obligation | $14,098,000 | $12,920,000 | $11,199,000 | $11,928,000 |
| Current Accrued Expenses | $91,454,000 | $74,704,000 | $51,627,000 | $79,839,000 |
| Investments And Advances | $250,983,000 | $242,337,000 | $255,857,000 | $25,000,000 |
| Other Investments | $15,000,000 | $0 | - | - |
| Goodwill | $980,935,000 | $972,663,000 | $872,737,000 | $822,101,000 |
| Net PPE | $319,118,000 | $342,439,000 | $324,526,000 | $288,798,000 |
| Accumulated Depreciation | $-286,131,000 | $-256,556,000 | $-233,712,000 | $-211,423,000 |
| Gross PPE | $605,249,000 | $598,995,000 | $558,238,000 | $500,221,000 |
| Construction In Progress | $23,420,000 | $39,749,000 | $15,491,000 | $21,729,000 |
| Other Properties | $73,399,000 | $91,285,000 | $98,326,000 | $65,556,000 |
| Machinery Furniture Equipment | $245,924,000 | $215,948,000 | $190,019,000 | $174,813,000 |
| Buildings And Improvements | $254,355,000 | $243,863,000 | $245,302,000 | $229,551,000 |
| Land And Improvements | $8,151,000 | $8,150,000 | $9,100,000 | $8,572,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $100,366,000 | $100,354,000 | $87,087,000 | $61,832,000 |
| Raw Materials | $89,080,000 | $79,377,000 | $84,551,000 | $79,291,000 |
| Other Short Term Investments | $0 | $1,072,000 | $23,739,000 | $74,462,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $256,550,000 | $236,104,000 | $216,149,000 | $280,364,000 |
| Operating Activities | ||||
| Operating Cash Flow | $287,556,000 | $298,981,000 | $254,393,000 | $325,272,000 |
| Cash Flow From Continuing Operating Activities | $287,556,000 | $298,981,000 | $254,393,000 | $325,272,000 |
| Operating Gains Losses | $-938,000 | $6,841,000 | $-47,715,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-31,006,000 | $-62,877,000 | $-38,244,000 | $-44,908,000 |
| Investing Cash Flow | $-35,183,000 | $-203,030,000 | $-265,649,000 | $-96,851,000 |
| Cash Flow From Continuing Investing Activities | $-35,183,000 | $-203,030,000 | $-265,649,000 | $-96,851,000 |
| Net Other Investing Changes | $2,447,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-275,731,000 | $-80,042,000 | $-19,562,000 | $-160,950,000 |
| Financing Cash Flow | $-253,905,000 | $-122,398,000 | $22,616,000 | $-242,853,000 |
| Cash Flow From Continuing Financing Activities | $-253,905,000 | $-122,398,000 | $22,616,000 | $-242,853,000 |
| Net Other Financing Charges | $-6,522,000 | $-21,872,000 | $-31,350,000 | $-23,373,000 |
| Cash Dividends Paid | $-50,391,000 | $-50,419,000 | $-50,285,000 | $-50,185,000 |
| Common Stock Dividend Paid | $-50,391,000 | $-50,419,000 | $-50,285,000 | $-50,185,000 |
| Net Common Stock Issuance | $-275,731,000 | $-80,042,000 | $-19,562,000 | $-160,950,000 |
| Dividends Received Cfi | $7,291,000 | $6,997,000 | $-232,000,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-77,000,000 | $-256,000,000 | $-525,661,000 | $-175,500,000 |
| Issuance Of Debt | $104,000,000 | $225,000,000 | $619,661,000 | $90,000,000 |
| Interest Paid Supplemental Data | $18,955,000 | $14,502,000 | $8,368,000 | $11,027,000 |
| Income Tax Paid Supplemental Data | $74,357,000 | $65,254,000 | $88,428,000 | $30,341,000 |
| End Cash Position | $162,186,000 | $151,791,000 | $180,571,000 | $172,567,000 |
| Beginning Cash Position | $151,791,000 | $180,571,000 | $172,567,000 | $199,091,000 |
| Effect Of Exchange Rate Changes | $11,927,000 | $-2,333,000 | $-3,356,000 | $-12,092,000 |
| Changes In Cash | $-1,532,000 | $-26,447,000 | $11,360,000 | $-14,432,000 |
| Proceeds From Stock Option Exercised | $51,739,000 | $60,935,000 | $29,813,000 | $77,155,000 |
| Common Stock Payments | $-275,731,000 | $-80,042,000 | $-19,562,000 | $-160,950,000 |
| Net Issuance Payments Of Debt | $27,000,000 | $-31,000,000 | $94,000,000 | $-85,500,000 |
| Net Long Term Debt Issuance | $27,000,000 | $-31,000,000 | $94,000,000 | $-85,500,000 |
| Long Term Debt Payments | $-77,000,000 | $-256,000,000 | $-525,661,000 | $-175,500,000 |
| Long Term Debt Issuance | $104,000,000 | $225,000,000 | $619,661,000 | $90,000,000 |
| Net Investment Purchase And Sale | $1,085,000 | $22,557,000 | $87,955,000 | $-51,943,000 |
| Sale Of Investment | $1,085,000 | $28,083,000 | $108,455,000 | $26,055,000 |
| Purchase Of Investment | $0 | $-5,526,000 | $-20,500,000 | $-77,998,000 |
| Net Business Purchase And Sale | $-15,000,000 | $-169,707,000 | $-83,360,000 | $0 |
| Sale Of Business | $0 | $0 | $17,824,000 | $0 |
| Purchase Of Business | $-15,000,000 | $-169,707,000 | $-101,184,000 | $0 |
| Net PPE Purchase And Sale | $-31,006,000 | $-62,877,000 | $-38,244,000 | $-44,908,000 |
| Purchase Of PPE | $-31,006,000 | $-62,877,000 | $-38,244,000 | $-44,908,000 |
| Change In Working Capital | $11,539,000 | $-10,106,000 | $-90,577,000 | $-69,517,000 |
| Change In Payables And Accrued Expense | $1,454,000 | $38,387,000 | $-32,466,000 | $23,168,000 |
| Change In Accrued Expense | $15,408,000 | $12,618,000 | $-24,558,000 | $7,760,000 |
| Change In Payable | $-13,954,000 | $25,769,000 | $-7,908,000 | $15,408,000 |
| Change In Account Payable | $-13,954,000 | $25,769,000 | $-7,908,000 | $12,741,000 |
| Change In Prepaid Assets | $-14,372,000 | $-3,146,000 | $-4,585,000 | $-3,082,000 |
| Change In Inventory | $-18,144,000 | $-14,215,000 | $-30,167,000 | $-32,007,000 |
| Change In Receivables | $42,601,000 | $-31,132,000 | $-23,359,000 | $-57,596,000 |
| Changes In Account Receivables | $34,132,000 | $-20,533,000 | $-20,867,000 | - |
| Other Non Cash Items | $2,111,000 | $-762,000 | $-9,658,000 | $-22,637,000 |
| Stock Based Compensation | $40,833,000 | $38,042,000 | $39,230,000 | $42,183,000 |
| Asset Impairment Charge | $101,815,000 | $24,597,000 | $0 | $19,261,000 |
| Deferred Tax | $-51,107,000 | $-39,447,000 | $-29,567,000 | $6,816,000 |
| Deferred Income Tax | $-51,107,000 | $-39,447,000 | $-29,567,000 | $6,816,000 |
| Depreciation Amortization Depletion | $109,903,000 | $111,711,000 | $107,238,000 | $101,069,000 |
| Depreciation And Amortization | $109,903,000 | $111,711,000 | $107,238,000 | $101,069,000 |
| Earnings Losses From Equity Investments | $-938,000 | $6,841,000 | $1,143,000 | $0 |
| Gain Loss On Sale Of Business | $0 | $0 | $-11,682,000 | $0 |
| Net Income From Continuing Operations | $73,400,000 | $168,105,000 | $285,442,000 | $263,099,000 |
| Change In Tax Payable | - | $-10,599,000 | $-2,492,000 | $2,667,000 |
| Change In Income Tax Payable | - | $-10,599,000 | $-2,492,000 | $2,667,000 |
| Unrealized Gain Loss On Investment Securities | - | $-283,000 | $-472,000 | $-15,002,000 |
| Net Short Term Debt Issuance | - | - | $619,661,000 | $-85,500,000 |
| Short Term Debt Issuance | - | - | $619,661,000 | $90,000,000 |
| Gain Loss On Investment Securities | - | - | $-37,176,000 | - |
| Short Term Debt Payments | - | - | - | $-175,500,000 |
Fetched: 2026-06-15